PT2114873E - Ligandos para imagiologia de inervação cardíaca - Google Patents
Ligandos para imagiologia de inervação cardíaca Download PDFInfo
- Publication number
- PT2114873E PT2114873E PT78697174T PT07869717T PT2114873E PT 2114873 E PT2114873 E PT 2114873E PT 78697174 T PT78697174 T PT 78697174T PT 07869717 T PT07869717 T PT 07869717T PT 2114873 E PT2114873 E PT 2114873E
- Authority
- PT
- Portugal
- Prior art keywords
- compounds
- imaging
- cardiac innervation
- beta
- fluoropropoxy
- Prior art date
Links
- 230000000747 cardiac effect Effects 0.000 title abstract 3
- 230000030214 innervation Effects 0.000 title abstract 3
- 238000003384 imaging method Methods 0.000 title abstract 2
- ZYULQCDNUYJBRI-UHFFFAOYSA-N 2-[[3-bromo-4-(3-fluoropropoxy)phenyl]methyl]guanidine Chemical compound NC(=N)NCC1=CC=C(OCCCF)C(Br)=C1 ZYULQCDNUYJBRI-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 229930194542 Keto Natural products 0.000 abstract 1
- 238000012879 PET imaging Methods 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000001743 benzylic group Chemical group 0.000 abstract 1
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical group OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000012216 imaging agent Substances 0.000 abstract 1
- 125000000468 ketone group Chemical group 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 238000009206 nuclear medicine Methods 0.000 abstract 1
- 238000012636 positron electron tomography Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/001—Acyclic or carbocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/56—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups
- C07C215/58—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
- C07C215/60—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain the chain having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/64—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
- C07C217/66—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain
- C07C217/70—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/06—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/08—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nuclear Medicine (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87721106P | 2006-12-26 | 2006-12-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2114873E true PT2114873E (pt) | 2013-05-06 |
Family
ID=39307501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT78697174T PT2114873E (pt) | 2006-12-26 | 2007-12-21 | Ligandos para imagiologia de inervação cardíaca |
Country Status (20)
| Country | Link |
|---|---|
| US (5) | US8491868B2 (enExample) |
| EP (5) | EP2474524A3 (enExample) |
| JP (3) | JP5656408B2 (enExample) |
| KR (4) | KR101810348B1 (enExample) |
| CN (3) | CN105622463B (enExample) |
| AU (1) | AU2007339954B2 (enExample) |
| BR (1) | BRPI0722082A8 (enExample) |
| CA (2) | CA2673853C (enExample) |
| CO (1) | CO6231002A2 (enExample) |
| DK (3) | DK2474523T3 (enExample) |
| ES (3) | ES2405655T3 (enExample) |
| IL (3) | IL199563A (enExample) |
| MX (2) | MX367292B (enExample) |
| PL (1) | PL2114873T3 (enExample) |
| PT (1) | PT2114873E (enExample) |
| RU (1) | RU2506256C2 (enExample) |
| SG (1) | SG177918A1 (enExample) |
| TW (2) | TWI618544B (enExample) |
| WO (1) | WO2008083056A2 (enExample) |
| ZA (1) | ZA200904828B (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7344702B2 (en) | 2004-02-13 | 2008-03-18 | Bristol-Myers Squibb Pharma Company | Contrast agents for myocardial perfusion imaging |
| PT2114873E (pt) | 2006-12-26 | 2013-05-06 | Lantheus Medical Imaging Inc | Ligandos para imagiologia de inervação cardíaca |
| PT3323810T (pt) | 2010-02-08 | 2022-04-14 | Lantheus Medical Imaging Inc | Sistema de reação automatizado, cassete e dispositivo para sintetizar agentes de imagem |
| EP3653230B1 (en) * | 2010-05-11 | 2023-05-10 | Lantheus Medical Imaging, Inc. | Compositions, methods and systems for the synthesis and use of imaging agents |
| WO2011143660A2 (en) | 2010-05-14 | 2011-11-17 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating leukemia |
| CN103180318B (zh) | 2010-05-14 | 2017-05-10 | 达那-法伯癌症研究所 | 雄性避孕组合物以及使用方法 |
| EP2902030B1 (en) | 2010-05-14 | 2016-09-14 | Dana-Farber Cancer Institute, Inc. | Thienotriazolodiazepine compounds for treating neoplasia |
| AR086113A1 (es) | 2011-04-30 | 2013-11-20 | Abbott Lab | Isoxazolinas como agentes terapeuticos |
| SG10201607437QA (en) * | 2011-09-09 | 2016-10-28 | Lantheus Medical Imaging Inc | Compositions, methods, and systems for the synthesis and use of imaging agents |
| SG11201406206RA (en) | 2012-04-10 | 2014-10-30 | Lantheus Medical Imaging Inc | Radiopharmaceutical synthesis methods |
| AU2013203000B9 (en) | 2012-08-10 | 2017-02-02 | Lantheus Medical Imaging, Inc. | Compositions, methods, and systems for the synthesis and use of imaging agents |
| WO2014052454A1 (en) * | 2012-09-25 | 2014-04-03 | The Regents Of The University Of Michigan | Imaging agents |
| US10939822B2 (en) | 2013-01-24 | 2021-03-09 | Tylerton International Holdings Inc. | Body structure imaging |
| CN104936623A (zh) * | 2013-01-24 | 2015-09-23 | 泰勒顿国际控股公司 | 神经元成像与治疗 |
| AU2014229201A1 (en) * | 2013-03-11 | 2015-09-10 | Tylerton International Inc. | Modeling the autonomous nervous system and uses thereof |
| CA2918910A1 (en) | 2013-07-25 | 2015-01-29 | Dana-Farber Cancer Institute, Inc. | Inhibitors of transcription factors and uses thereof |
| CN105705080B (zh) * | 2013-09-08 | 2020-05-01 | 泰勒顿国际公司 | 用于诊断和治疗神经系统活动影响疾病模式的装置和方法 |
| EP3066101B1 (en) | 2013-11-08 | 2020-07-29 | Dana-Farber Cancer Institute, Inc. | Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors |
| CN106102583B (zh) | 2014-01-10 | 2024-08-09 | 泰勒顿国际控股公司 | 瘢痕和纤维心脏区的检测 |
| KR20160115953A (ko) | 2014-01-31 | 2016-10-06 | 다나-파버 캔서 인스티튜트 인크. | 디아미노피리미딘 벤젠술폰 유도체 및 그의 용도 |
| JP2017504651A (ja) | 2014-01-31 | 2017-02-09 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | ジアゼパン誘導体の使用 |
| CN106456653A (zh) | 2014-02-28 | 2017-02-22 | 腾沙治疗公司 | 高胰岛素血症相关病症的治疗 |
| US10776961B2 (en) | 2014-07-30 | 2020-09-15 | Navix International Limited | Registering nuclear medicine data |
| JP2017526741A (ja) | 2014-08-08 | 2017-09-14 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | ジアゼパン誘導体およびその使用 |
| CN106793775B (zh) | 2014-08-08 | 2020-06-02 | 达纳-法伯癌症研究所股份有限公司 | 二氢碟啶酮衍生物及其用途 |
| WO2016201370A1 (en) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| HK1256419A1 (zh) | 2015-09-11 | 2019-09-20 | 达纳-法伯癌症研究所股份有限公司 | 乙酰胺噻吩並三唑並二氮雜環庚三烯及其用途 |
| PE20181287A1 (es) | 2015-09-11 | 2018-08-07 | Dana Farber Cancer Inst Inc | Ciano tienotriazolpirazinas y usos de las mismas |
| SG10201913450PA (en) | 2015-11-25 | 2020-03-30 | Dana Farber Cancer Inst Inc | Bivalent bromodomain inhibitors and uses thereof |
| CN107892651A (zh) * | 2017-11-29 | 2018-04-10 | 陕西慧康生物科技有限责任公司 | 一种合成dl‑盐酸麻黄碱的方法 |
| WO2020081410A2 (en) * | 2018-10-15 | 2020-04-23 | Bristol-Myers Squibb Company | Radioligands for imaging the lpa1 receptor |
| EP3682906A1 (en) * | 2019-01-17 | 2020-07-22 | Julius-Maximilians-Universität Würzburg | Compound targeting norepinephrine transporter |
| CN109748825B (zh) * | 2019-02-01 | 2022-02-18 | 原子高科股份有限公司 | 一种18f标记的胍甲基取代苯类似物及其应用 |
| KR102690858B1 (ko) | 2020-07-14 | 2024-08-02 | 한국과학기술원 | 이산화탄소와 개미산만으로 성장 가능한 재조합 미생물 및 상기 재조합 미생물을 이용하여 유용물질을 제조하는 방법 |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6012A (en) * | 1849-01-09 | Lithographing co | ||
| FR1010218A (fr) | 1949-02-10 | 1952-06-09 | American Cyanamid Co | Perfectionnements aux sels de guanidine |
| GB1215255A (en) | 1968-03-13 | 1970-12-09 | Pfizer & Co C | Halophenylalkylguanidine compounds |
| US4094881A (en) | 1976-03-10 | 1978-06-13 | Smithkline Corporation | Process for preparing triazolethiols |
| US4275074A (en) | 1979-03-09 | 1981-06-23 | Graham J. Dobbie | Catecholamine treatment of ocular hypertension |
| US4270537A (en) | 1979-11-19 | 1981-06-02 | Romaine Richard A | Automatic hypodermic syringe |
| US4258188A (en) * | 1980-02-04 | 1981-03-24 | American Home Products Corporation | 2-(1-Piperazinyl)-cycloheptimidazole derivatives |
| US4622217A (en) * | 1984-04-27 | 1986-11-11 | The Regents Of The University Of Michigan | I-4-amino-3-iodobenzylguanidine as imaging and therapeutic agent |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US4886499A (en) | 1986-12-18 | 1989-12-12 | Hoffmann-La Roche Inc. | Portable injection appliance |
| GB8704027D0 (en) | 1987-02-20 | 1987-03-25 | Owen Mumford Ltd | Syringe needle combination |
| AU1503888A (en) * | 1987-04-24 | 1988-10-27 | King Faisal Specialist Hospital & Research Centre | Method of producing iodine124 and meta-iodobenzlyguanidine containing iodine124 |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4940460A (en) | 1987-06-19 | 1990-07-10 | Bioject, Inc. | Patient-fillable and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US5339163A (en) | 1988-03-16 | 1994-08-16 | Canon Kabushiki Kaisha | Automatic exposure control device using plural image plane detection areas |
| FR2638359A1 (fr) | 1988-11-03 | 1990-05-04 | Tino Dalto | Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5190521A (en) | 1990-08-22 | 1993-03-02 | Tecnol Medical Products, Inc. | Apparatus and method for raising a skin wheal and anesthetizing skin |
| US5527288A (en) | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
| GB9118204D0 (en) | 1991-08-23 | 1991-10-09 | Weston Terence E | Needle-less injector |
| SE9102652D0 (sv) | 1991-09-13 | 1991-09-13 | Kabi Pharmacia Ab | Injection needle arrangement |
| US5565449A (en) * | 1991-10-18 | 1996-10-15 | Genentech, Inc. | Nonpeptidyl integrin inhibitors having specificity for the GPIIb IIIa receptor |
| US5328483A (en) | 1992-02-27 | 1994-07-12 | Jacoby Richard M | Intradermal injection device with medication and needle guard |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US5569189A (en) | 1992-09-28 | 1996-10-29 | Equidyne Systems, Inc. | hypodermic jet injector |
| US5334144A (en) | 1992-10-30 | 1994-08-02 | Becton, Dickinson And Company | Single use disposable needleless injector |
| TW279864B (enExample) * | 1993-02-19 | 1996-07-01 | Janssen Pharmaceutica Nv | |
| US5879657A (en) * | 1993-03-30 | 1999-03-09 | The Dupont Merck Pharmaceutical Company | Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders |
| EP0639573A1 (de) * | 1993-08-03 | 1995-02-22 | Hoechst Aktiengesellschaft | Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament |
| WO1995024176A1 (en) | 1994-03-07 | 1995-09-14 | Bioject, Inc. | Ampule filling device |
| US5466220A (en) | 1994-03-08 | 1995-11-14 | Bioject, Inc. | Drug vial mixing and transfer device |
| US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
| US5730723A (en) | 1995-10-10 | 1998-03-24 | Visionary Medical Products Corporation, Inc. | Gas pressured needle-less injection device and method |
| US5874573A (en) | 1995-06-26 | 1999-02-23 | Concat, Inc. | Compounds with chelation affinity and selectivity for first transition series elements: use in medical therapy |
| US5893397A (en) | 1996-01-12 | 1999-04-13 | Bioject Inc. | Medication vial/syringe liquid-transfer apparatus |
| GB9607549D0 (en) | 1996-04-11 | 1996-06-12 | Weston Medical Ltd | Spring-powered dispensing device |
| TW499412B (en) | 1996-11-26 | 2002-08-21 | Dimensional Pharm Inc | Aminoguanidines and alkoxyguanidines as protease inhibitors |
| ES2270475T3 (es) | 1996-11-27 | 2007-04-01 | Bristol-Myers Squibb Pharma Company | Nuevos antagonistas de receptores de integrina. |
| US5993412A (en) | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
| CA2345710C (en) * | 1997-10-02 | 2008-12-30 | The University Of Western Ontario | Preparation of radiolabelled haloaromatics via polymer-bound intermediates |
| IT1298087B1 (it) | 1998-01-08 | 1999-12-20 | Fiderm S R L | Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni |
| AU3406599A (en) | 1998-04-09 | 1999-11-01 | Institut Fur Diagnostikforschung Gmbh An Der Freien Universitat Berlin | Novel benzyl guanidine derivatives for therapy and (in-vivo) and (in-vitro) diagnosis |
| AU5671699A (en) | 1998-08-14 | 2000-03-06 | Smithkline Beecham Corporation | Grp receptor ligands |
| US6511648B2 (en) | 1998-12-18 | 2003-01-28 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
| US6656448B1 (en) | 2000-02-15 | 2003-12-02 | Bristol-Myers Squibb Pharma Company | Matrix metalloproteinase inhibitors |
| GB0019357D0 (en) | 2000-08-07 | 2000-09-27 | Melacure Therapeutics Ab | Novel phenyl guanidines |
| DE10114561A1 (de) | 2001-03-24 | 2002-09-26 | Wella Ag | Verwendung von Mitteln enthaltend Kreatin, Kreatin und/oder deren Derivaten zur Verstärkung und Strukturverbesserung von keratinischen Fasern |
| US7344702B2 (en) | 2004-02-13 | 2008-03-18 | Bristol-Myers Squibb Pharma Company | Contrast agents for myocardial perfusion imaging |
| PL373598A1 (en) | 2002-08-17 | 2005-09-05 | Altana Pharma Ag | Novel benzonaphthyridines |
| WO2004037166A2 (en) | 2002-09-17 | 2004-05-06 | Isis Pharmaceuticals, Inc. | Therapeutic guanidines |
| CA2530087A1 (en) * | 2003-06-30 | 2005-02-03 | Merck & Co., Inc. | Radiolabeled cannabinoid-1 receptor modulators |
| EP1691777A4 (en) | 2003-12-01 | 2010-10-13 | Medi Physics Inc | NEW DIFFERENTIAL IMAGING METHOD |
| US20060100225A1 (en) | 2004-03-23 | 2006-05-11 | Xi Chen | Heteroaryl guanidines; inhibitors of viral replication |
| WO2005115971A1 (ja) * | 2004-05-28 | 2005-12-08 | Hamamatsu Photonics K.K. | 放射性チロシン誘導体、その製造方法、放射性チロシン誘導体からなるポジトロンイメージング用標識剤及び腫瘍の悪性度評価薬剤並びに腫瘍の検出方法 |
| ATE493152T1 (de) | 2004-09-23 | 2011-01-15 | Guerbet Sa | Liposomale kontrastmittel für die cest-bildgebung |
| US20060083681A1 (en) | 2004-10-18 | 2006-04-20 | Ajay Purohit | Compounds for myocardial perfusion imaging |
| US7534418B2 (en) * | 2004-12-10 | 2009-05-19 | The Regents Of The University Of Michigan | Imaging agents |
| GB0512770D0 (en) | 2005-06-23 | 2005-07-27 | Hammersmith Imanet Ltd | Imaging compounds |
| AU2007332641A1 (en) | 2006-12-13 | 2008-06-19 | F. Hoffmann-La Roche Ag | Novel 2 -imidazoles as ligands for trace amine associated receptors (TAAR) |
| GB0625523D0 (en) | 2006-12-21 | 2007-01-31 | Ge Healthcare Ltd | In vivo imaging agents |
| PT2114873E (pt) | 2006-12-26 | 2013-05-06 | Lantheus Medical Imaging Inc | Ligandos para imagiologia de inervação cardíaca |
| WO2008082305A1 (en) | 2006-12-28 | 2008-07-10 | Raufoss Technology As | Control arm |
| WO2008115593A1 (en) | 2007-03-21 | 2008-09-25 | The University Of Montana | 1-[(2'-substituted)-piperazin-1'-yl]-isoquinolines as norepinephrine transporter inhibitor therapeutics and positron emission tomography imaging agents |
| US8653282B2 (en) | 2007-10-18 | 2014-02-18 | Boehringer Ingelheim International Gmbh | Preparation of dihydrothieno [3,2-D] pyrimidines and intermediates used therein |
| WO2010015340A1 (en) | 2008-08-06 | 2010-02-11 | Bayer Schering Pharma Aktiengesellschaft | Daa-pyridine as peripheral benzodiazepine receptor ligand for diagnostic imaging and pharmaceutical treatment |
| GB0906274D0 (en) | 2009-04-09 | 2009-05-20 | Ge Healthcare Ltd | Imaging the central nervous system |
| WO2010120368A2 (en) | 2009-04-15 | 2010-10-21 | Lantheus Medical Imaging, Inc. | Stabilization of radiopharmaceutical compositions using ascorbic acid |
| CN101555232B (zh) | 2009-05-21 | 2011-01-05 | 北京师范大学 | 氟-18标记哒嗪酮类化合物及制备方法和应用 |
| WO2011005322A2 (en) | 2009-07-08 | 2011-01-13 | Lantheus Medical Imaging, Inc. | N-alkoxyamide conjugates as imaging agents |
| PT3323810T (pt) | 2010-02-08 | 2022-04-14 | Lantheus Medical Imaging Inc | Sistema de reação automatizado, cassete e dispositivo para sintetizar agentes de imagem |
| EP3653230B1 (en) | 2010-05-11 | 2023-05-10 | Lantheus Medical Imaging, Inc. | Compositions, methods and systems for the synthesis and use of imaging agents |
| SG10201607437QA (en) | 2011-09-09 | 2016-10-28 | Lantheus Medical Imaging Inc | Compositions, methods, and systems for the synthesis and use of imaging agents |
| EP2671575A1 (en) | 2012-06-04 | 2013-12-11 | Universität Regensburg | Ras inhibitors |
| JP2017131851A (ja) | 2016-01-29 | 2017-08-03 | 日本特殊陶業株式会社 | マイクロ波加熱用触媒材料、マイクロ波加熱用触媒体、及び、その製造方法 |
-
2007
- 2007-12-21 PT PT78697174T patent/PT2114873E/pt unknown
- 2007-12-21 EP EP12152816A patent/EP2474524A3/en active Pending
- 2007-12-21 AU AU2007339954A patent/AU2007339954B2/en active Active
- 2007-12-21 SG SG2011095601A patent/SG177918A1/en unknown
- 2007-12-21 EP EP12152815.2A patent/EP2474523B1/en active Active
- 2007-12-21 EP EP12152817.8A patent/EP2474525B1/en active Active
- 2007-12-21 CN CN201510856954.7A patent/CN105622463B/zh not_active Expired - Fee Related
- 2007-12-21 JP JP2009544215A patent/JP5656408B2/ja active Active
- 2007-12-21 US US12/448,575 patent/US8491868B2/en active Active
- 2007-12-21 BR BRPI0722082A patent/BRPI0722082A8/pt not_active Application Discontinuation
- 2007-12-21 DK DK12152815.2T patent/DK2474523T3/da active
- 2007-12-21 TW TW105113601A patent/TWI618544B/zh not_active IP Right Cessation
- 2007-12-21 KR KR1020167010430A patent/KR101810348B1/ko not_active Expired - Fee Related
- 2007-12-21 KR KR1020097015613A patent/KR101718160B1/ko not_active Expired - Fee Related
- 2007-12-21 CA CA2673853A patent/CA2673853C/en active Active
- 2007-12-21 ES ES07869717T patent/ES2405655T3/es active Active
- 2007-12-21 KR KR1020177024416A patent/KR20170102580A/ko not_active Ceased
- 2007-12-21 MX MX2014010520A patent/MX367292B/es unknown
- 2007-12-21 TW TW096149600A patent/TWI549692B/zh not_active IP Right Cessation
- 2007-12-21 CN CN200780051773.0A patent/CN101687780B/zh not_active Expired - Fee Related
- 2007-12-21 WO PCT/US2007/088500 patent/WO2008083056A2/en not_active Ceased
- 2007-12-21 EP EP07869717A patent/EP2114873B1/en active Active
- 2007-12-21 DK DK12152817.8T patent/DK2474525T3/da active
- 2007-12-21 CN CN201910053427.0A patent/CN110003079A/zh active Pending
- 2007-12-21 DK DK07869717.4T patent/DK2114873T3/da active
- 2007-12-21 ES ES12152817T patent/ES2805286T3/es active Active
- 2007-12-21 EP EP12152818A patent/EP2474526A3/en not_active Withdrawn
- 2007-12-21 CA CA2984226A patent/CA2984226C/en active Active
- 2007-12-21 ES ES12152815T patent/ES2804801T3/es active Active
- 2007-12-21 MX MX2009007018A patent/MX2009007018A/es active IP Right Grant
- 2007-12-21 RU RU2009128591/04A patent/RU2506256C2/ru active
- 2007-12-21 PL PL07869717T patent/PL2114873T3/pl unknown
- 2007-12-21 KR KR1020147032350A patent/KR20140140134A/ko not_active Ceased
-
2009
- 2009-06-25 IL IL199563A patent/IL199563A/en active IP Right Grant
- 2009-07-09 ZA ZA2009/04828A patent/ZA200904828B/en unknown
- 2009-07-22 CO CO09076173A patent/CO6231002A2/es active IP Right Grant
-
2013
- 2013-01-24 IL IL224396A patent/IL224396B/en active IP Right Grant
- 2013-06-12 US US13/916,205 patent/US10010631B2/en active Active
-
2014
- 2014-07-25 JP JP2014152244A patent/JP6021860B2/ja active Active
-
2016
- 2016-04-21 JP JP2016085372A patent/JP2016183164A/ja active Pending
-
2017
- 2017-08-07 IL IL253885A patent/IL253885A0/en unknown
-
2018
- 2018-05-22 US US15/986,680 patent/US11241509B2/en active Active
-
2022
- 2022-01-28 US US17/587,454 patent/US12324845B2/en active Active
-
2025
- 2025-01-17 US US19/027,961 patent/US20250161500A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2114873E (pt) | Ligandos para imagiologia de inervação cardíaca | |
| RU2386626C2 (ru) | 1a, 5a-ТЕТРАГИДРО-S-ТИАЦИКЛОПРОПА[a]ПЕНТАЛЕНЫ:ТРИЦИКЛИЧЕСКИЕ ПРОИЗВОДНЫЕ ТИОФЕНА В КАЧЕСТВЕ АГОНИСТОВ РЕЦЕПТОРОВ S1P1/EDG1 | |
| FR20C1018I1 (fr) | Composition pharmaceutique comprenant du glycopyrrolate et un agoniste du récepteur beta2 adrénergique | |
| CY1111310T1 (el) | Ενωσεις για την αγωγη μεταβολικων διαταραχων | |
| NZ592258A (en) | Pesticidal (hetero) arylpyrrolidines | |
| JP2004516293A5 (enExample) | ||
| ATE530066T1 (de) | Verbindungen zur behandlung von stoffwechselstörungen | |
| WO2004073611A3 (en) | Compounds for the treatment of metabolic disorders | |
| MX2010003603A (es) | Metodo para el tratamiento de enfermedades de riñon poliquisticas con derivados de ceramida. | |
| RU2394031C2 (ru) | Соли четвертичного аммония в качестве антагонистов м3 | |
| MX2009003916A (es) | Compuestos heterociclicos utiles como agentes anabolicos para animales de ganado. | |
| MXPA05011592A (es) | Compuestos para el tratamiento de trastornos metabolicos. | |
| UA95613C2 (ru) | Соединения для лечения расстройсв метаболизма | |
| DE602004024382D1 (de) | Verbindungen zur behandlung von stoffwechselstörungen | |
| CO5180605A1 (es) | Compuestos de indol | |
| BRPI0409049A (pt) | métodos de preparação de um composto, composição e composição cristalina | |
| SE8304513D0 (sv) | Derivatvies of omega-amino acids, the preparation and utilisation thereof, and the compositions containing these derivatives | |
| CA2400856A1 (en) | Imaging agents for diagnosis of parkinson's disease | |
| RU2384573C2 (ru) | Пиразол- и фенилпроизводные в качестве ингибиторов ppar | |
| MX2021013849A (es) | 4-[5-[(rac)-1-[5-(3-clorofenil)-3-isoxazolil]etoxi]-4-metil-4h-1, 2,4-triazol-3-il]piridina para usar en la prevencion y/o el tratamiento del dolor en un animal. | |
| EP2048148A4 (en) | METHYLAQUOCOBYRINIC ACID DERIVATIVE, ALKYLATION COMPOSITION AND METHOD FOR DETACHING HARMFUL COMPOUNDS USING THE COMPOSITION | |
| CY1114152T1 (el) | Ν-[3-βρωμο-4-(3-[18f]φθοροπροποξυ)-βενζυλο]-γουανιδινη για απεικονιση της καρδιακης εννευρωσης | |
| KR910007875A (ko) | 도파민 길항제로서의 벤질피롤리딘 유도체 | |
| GEP20094787B (en) | Pharmaceutical composition comprising a 1-(3-chloro-phenyl)-3-alkyl piperazine for treating appetite disorder | |
| WO2007076601B1 (en) | Imaging of d2high receptors using radiolabelled (-)- quinpirole and analogs thereof |